BioLineRx Ltd.

NasdaqCM:BLRX Stock Report

Market Cap: US$13.5m

BioLineRx Management

Management criteria checks 4/4

BioLineRx's CEO is Phil Serlin, appointed in Oct 2016, has a tenure of 9.58 years. total yearly compensation is $641.00K, comprised of 46.2% salary and 53.8% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $26.52K. The average tenure of the management team and the board of directors is 9.6 years and 4.4 years respectively.

Key information

Phil Serlin

Chief executive officer

US$641.0k

Total compensation

CEO salary percentage46.18%
CEO tenure9.6yrs
CEO ownership0.2%
Management average tenure9.6yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Seeking Alpha • Sep 19

BioLineRx stock slips on $15M securities offering

BioLineRx (NASDAQ:BLRX) shares dropped 30% pre-market on Monday after the biopharmaceutical company announced a $15M securities offering. The firm entered into definitive agreements with several institutional investors for the issuance and sale of 13,636,365 of its American Depositary Shares and warrants to purchase up to 13,636,365 ADSs at a combined purchase price of $1.10 per ADS and associated warrant. Each ADS represents 15 ordinary shares, par value NIS 0.10 per share, of BioLineRx. The warrants will have an exercise price of $1.15/ADS and will be exercisable at any time upon issuance and will expire five years from the date of issuance. Gross proceeds from the offering are expected to be $15M. Net proceeds will be used to facilitate the commercial launch of Motixafortide in autologous stem cell mobilization for multiple myeloma patients and general corporate purposes, which may include working capital and funding clinical trials. The offering is expected to close on or about Sep 21, 2022.
Seeking Alpha • Sep 12

BioLineRx files for FDA approval of motixafortide in stem cell mobilization

BioLineRx (NASDAQ:BLRX) submitted its new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Motixafortide in stem cell mobilization (SCM) for autologous bone marrow transplantation for patients with multiple myeloma. The NDA was backed by data from a phase 3 trial called GENESIS, which had met all main and secondary goals, the company said in a Sept. 12 press release. BioLineRx expects a decision on the NDA acceptance by the FDA in November. BLRX -4.40% to $1.74 premarket Sept. 12.
Seeking Alpha • Aug 16

biolinerx GAAP EPS of -$0.01 beats by $0.08

biolinerx press release (NASDAQ:BLRX): Q2 GAAP EPS of -$0.01 beats by $0.08. Ended the second quarter, with cash and cash equivalents of $43.2 million, sufficient to fund operations, as currently planned, into the first half of 2024.
Seeking Alpha • Jun 29

BioLineRx, GenFleet to co-develop Motixafortide treatment for a type of pancreatic cancer

M.S.Q. Ventures on Wednesday said its client BioLineRx (NASDAQ:BLRX) had entered into an agreement with China-based GenFleet Therapeutics for the co-development of inhibitor Motixafortide to treat a type of pancreatic cancer called pancreatic ductal adenocarcinoma (PDAC). As per the deal, GenFleet will design and run a randomized phase 2b clinical trial that will enroll about 200 first-line metastatic PDAC patients in China. The trial will evaluate the superiority of Motixafortide in combination with anti-PD-1 and chemotherapy vs. chemotherapy alone. U.S.-listed shares of BLRX were down 3.9% at $1.25 in premarket trading.
Seeking Alpha • Jun 30

BioLineRx: A Top Candidate For A Takeover Before 2022 Ends

On May 4, the company crossed successfully a crucial hurdle, putting it en-route toward getting an FDA approval as early as next year. As is the case with all micro-cap biotechs, investors remain skeptical due to the expected cash burn until, surely after, a possible approval. Not only does BioLineRx has sufficient liquidity for the next two years, but there are additional catalysts along the next 18 months. We believe that BLRX has a good chance to be bought out for a stock price in the mid-high teens, possibly before 2022 comes to an end.

CEO Compensation Analysis

How has Phil Serlin's remuneration changed compared to BioLineRx's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$641kUS$296k

-US$1m

Sep 30 2025n/an/a

-US$3m

Jun 30 2025n/an/a

-US$8m

Mar 31 2025n/an/a

-US$3m

Dec 31 2024US$764kUS$296k

-US$9m

Sep 30 2024n/an/a

-US$20m

Jun 30 2024n/an/a

-US$30m

Mar 31 2024n/an/a

-US$49m

Dec 31 2023US$952kUS$280k

-US$61m

Sep 30 2023n/an/a

-US$52m

Jun 30 2023n/an/a

-US$43m

Mar 31 2023n/an/a

-US$32m

Dec 31 2022US$1mUS$297k

-US$25m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$22m

Mar 31 2022n/an/a

-US$22m

Dec 31 2021US$903kUS$290k

-US$27m

Sep 30 2021n/an/a

-US$35m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$34m

Dec 31 2020US$958kUS$250k

-US$30m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$27m

Mar 31 2020n/an/a

-US$26m

Dec 31 2019US$678kUS$256k

-US$25m

Compensation vs Market: Phil's total compensation ($USD641.00K) is about average for companies of similar size in the US market ($USD627.70K).

Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.

CEO

Phil Serlin (65 yo)

9.6yrs
Tenure
US$641,000
Compensation

Mr. Philip A. Serlin, also known as Phil, CPA, MBA has been the Chief Executive Officer at BioLineRx, Ltd., since October 10, 2016. Mr. Serlin served as the Chief Financial and Operating Officer of BioLine...

Leadership Team

NamePositionTenureCompensationOwnership
Philip Serlin
Chief Executive Officer9.6yrsUS$641.00k0.20%
$ 26.5k
Mali Zeevi
Chief Financial Officer9.6yrsUS$360.00k0.050%
$ 6.8k
Ella Sorani
Chief Development Officer9.3yrsUS$398.00k0.0026%
$ 344.0
John Lacey
Head of Corporate Communications & Investor Relationsno datano datano data
Raziel Fried
Treasurer & Budgetary Control Directorno datano datano data
9.6yrs
Average Tenure
57yo
Average Age

Experienced Management: BLRX's management team is seasoned and experienced (9.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Aharon Schwartz
Independent Chairman of the Board22.3yrsno data0.14%
$ 19.1k
Sandra Panem
Independent Director12.3yrsno datano data
Avraham Molcho
Independent Director15.8yrsUS$26.55kno data
Raphael Hofstein
Independent Director23.3yrsUS$140.92kno data
Ronald Levy
Member of Immuno-Oncology Scientific Advisory Board4.4yrsno datano data
Rami Dar
Independent Director3.8yrsno datano data
Gal Cohen
Independent Director2.4yrsno datano data
Barbar-Jean Bormann-Kennedy
Independent Director12.8yrsno datano data
Jon Marc Wigginton
Member of Immuno-Oncology Scientific Advisory Board4.4yrsno datano data
Ignacio Melero Bermejo
Member of Immuno-Oncology Scientific Advisory Board4.4yrsno datano data
Aurelien Marabelle
Member of Immuno-Oncology Scientific Advisory Board4.4yrsno datano data
Shaoyu Yan
Director2.5yrsno datano data
4.4yrs
Average Tenure
67yo
Average Age

Experienced Board: BLRX's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/15 08:50
End of Day Share Price 2026/05/14 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioLineRx Ltd. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael KingCitizens JMP Securities, LLC
Joseph PantginisH.C. Wainwright & Co.
Justin WalshJonesTrading Institutional Services, LLC